Navigation Links
University of Kentucky Medical Center Transplants State's 1st SynCardia Total Artificial Heart Patient
Date:9/13/2012

TUCSON, Ariz., Sept. 13, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that University of Kentucky (UK) Medical Center has successfully transplanted its first patient to receive the SynCardia temporary Total Artificial Heart. Zack Poe, 21, received his matching donor heart in July after five months of life with the Total Artificial Heart.

(Photo: http://photos.prnewswire.com/prnh/20120913/LA73638)

"When we first met Zack, we knew that he was the perfect candidate to receive the Total Artificial Heart as a bridge to transplant," said Dr. Charles Hoopes, director of the UK Transplant Center. "The Total Artificial Heart worked exactly as we had planned, and it allowed Zack to gain back his strength before receiving an appropriate donor heart."

Zack was first diagnosed with heart failure in January, when an echocardiogram revealed that his ejection fraction -- a measurement of how much blood the heart pumps out to the body during each beat -- was less than 10 percent. He was referred to UK Medical Center for advanced treatment options, and about a week and a half after his initial diagnosis, his liver began to fail.

In order to save Zack's life, UK Medical Center completed SynCardia's four-phase certification program in a record 25 days. Zach was implanted with the Total Artificial Heart on Feb. 10. Less than a month later, on March 5, he was discharged from the hospital to wait for a matching donor heart at home with his family using the Freedom® portable driver.

"The transplant team here at UK is second to none, and patients like Zack are living proof," said Dr. Jay Zwischenberger, surgeon-in-chief at UK HealthCare. "The fact that Zack and his family did not have to leave the state for treatment shows the great strides UK HealthCare has made in our ability to provide care for Kentuckians with even the most complex health issues."

Weighing 13.5 pounds, the Freedom portable driver is the world's first wearable power supply for the SynCardia Total Artificial Heart. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S. On April 24, SynCardia completed the minimum enrollment required by the clinical study.

View news coverage of Zack's transplant
Read press release from UK Medical Center

Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn

CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 1,000 implants of the Total Artificial Heart, accounting for more than 270 patient years of life.

Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

SynCardia Wins Two Gold Stevies® at 2012 American Business Awards

On June 18, 2012, SynCardia was honored with two Gold Stevie® Awards at the 10th Annual American Business Awards. SynCardia won "Company of the Year – Health Products and Services" and "Most Innovative Company of the Year – up to 100 Employees." See the full list of SynCardia Awards & Recognition, which includes accolades from Forbes, Fast Company and more.


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Islet Sciences Announces Exclusive License Agreement with the University of California (UCLA) to Commercialize Small Molecules for Islet Expansion
2. University of California, San Francisco (UCSF) Selects Conflict of Interest Management System
3. OncoSec Secures License for Electroporation Intellectual Property from University of South Florida
4. Islet Sciences Announces Exclusive License Agreement with Winthrop University Hospital to Commercialize a Beta Cell Loss Measurement Technology in Diabetes
5. First Evidence that Adipose Stem Cell-Based Critical Limb Ischemia Treatment is Safe & Effective is published in Circulation Journal by Lead Investigator Dr. Han Cheol Lee of Pusan National University
6. University of Miami study finds RBAC to possess promising immunomodulating effects with respect to natural killer cell and cytokine activity
7. Northwestern University Joins VIVO Network with Elseviers SciVal Experts
8. Chicago Celebrates First Informatics Week, Co-Chaired by Intelligent Medical Objects and Northwestern University
9. Worlds smallest semiconductor laser created by University of Texas scientists
10. Genetics Policy Institute (GPI) Collaborates on Second Midwest Conference on Stem Cell Biology and Therapy, Oct. 5-7 at Oakland University
11. University of Utah physicists invent spintronic LED
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... Colo. (PRWEB) , ... January 11, 2017 , ... ... the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent ... despite a median 5 previous treatment regimens. Twenty-seven percent of these heavily pretreated ...
(Date:1/11/2017)... 2017  Brian Mehling, M.D., world-renowned stem cell researcher, ... International (BHI), will be attending the 47th Annual World ... from January 17-20, 2017. This will be Dr. Mehling,s ... theme of this year,s forum is Responsive and Responsible ... address strategies for fostering greater social inclusion and human ...
(Date:1/11/2017)... ... 2017 , ... IsoPlexis Corporation (IsoPlexis), a venture-capital ... the proteomic function of individual cells in patients, today announced it was recently ... National Institute on Aging of the National Institutes of Health to develop a ...
(Date:1/11/2017)... ... January 11, 2017 , ... Advanced Polymer ... its team. Bernhard Bartylla will lead European initiatives for APMT’s product lines serving ... ACOMP and ARGEN to European manufacturers and researchers. Bernhard brings significant experience in ...
Breaking Biology Technology:
(Date:12/16/2016)...   IdentyTechSolutions America LLC , a leading ... and a cutting-edge manufacturer of software and hardware ... seamless, integrated solutions that comprise IDT biometric readers ... provide IdentyTech,s customers with combined physical identification and ... and theft. "We are proud to ...
(Date:12/15/2016)... 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... announced today that on December 13, 2016, it received ... Nasdaq Stock Market LLC which acknowledged that, as of ... common stock had been at $1.00 or greater for ... with Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)... Dec. 14, 2016 "Increase in mobile transactions ... The mobile biometrics market is expected to grow from ... by 2022, at a CAGR of 29.3% between 2016 ... as the growing demand for smart devices, government initiatives, ... "Software component is expected to grow at a ...
Breaking Biology News(10 mins):